Hangzhou Trylead Chemical Technology

Trylead Biotech is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to the discovery and development of novel small molecule drugs for oncology. Founded by industry veterans with extensive experience in global pharmaceutical companies, Trylead focuses on targeting key signaling pathways in cancer, such as those involving cyclin-dependent kinases and tropomyosin receptor kinases. The company's lead program, TSN084, is a first-in-class multi-kinase inhibitor designed to treat a variety of solid tumors and hematological malignancies. With a robust R&D center in Shanghai and headquarters in Hangzhou, Trylead aims to address significant unmet medical needs through precision medicine and innovative chemical scaffolds.